Gilead has a wide array of commercial therapies plus a large pipeline and is particularly strong within the antiviral domain. The company had a particularly strong 2020 backed by the increased consumption of its remdesivir therapy that was administered to hospitalized COVID-19 patients all over the world. However, with the hospitalizations going down and the vaccinations taking place rapidly coupled with new competition emerging in the COVID-19 treatment domain, the company has to go back to relying on its HIV therapies as well as those in the oncological space that it has gotten access to, through recent acquisitions. We are optimistic about Gilead’s future and we expect the stock to have a decent performance in 2021.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
Want unlimited access to our reports? Purchase our $496 annual subscription!